Obesity: A review of pathogenesis and management strategies

Canadian Journal of Gastroenterology

Volumn 22, Issue 1, 2008, Pages 61-68

  Kaila, Brinderjit ^a   Raman, Maitreyi ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Management; Obesity; Pathogenesis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHOLECYSTOKININ; GHRELIN; GLUCAGON LIKE PEPTIDE 1; HORMONE; INTERLEUKIN 6; LEPTIN; MONOAMINE OXIDASE INHIBITOR; PEPTIDE YY; PLACEBO; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL CRAMP; ANXIETY; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; BLOOD PRESSURE; BODY MASS; CANADA; CARDIOVASCULAR DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEVELOPED COUNTRY; DIAGNOSTIC PROCEDURE; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENDOSCOPY; ENVIRONMENTAL FACTOR; FECES INCONTINENCE; FLATULENCE; HEREDITY; HUMAN; INSOMNIA; LIQUID FECES; LOW CALORY DIET; LOW FAT DIET; MOOD CHANGE; NAUSEA; NERVOUSNESS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PATIENT ATTITUDE; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEATORRHEA; SURGICAL TECHNIQUE; TACHYCARDIA; VERY LOW CALORY DIET; VITAMIN DEFICIENCY; VOMITING; XEROSTOMIA;

EID: 40749106081     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/609039     Document Type: Review

References (58)

1. Statistics Canada. Canadian Community Health Survey, 2004.
2. Young LR, Nestle M. The contribution of expanding portion sizes to the US obesity epidemic. Am J Public Health 2002;92:246-9.
3. Birmingham CL, Muller JL, Palepu A, Spinelli JJ, Anis AH. The cost of obesity in Canada. CMAJ 1999;160:483-8.
4. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
5. Hubscher SG. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2004;16:1107-15.
6. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-21.
7. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:315-22.
8. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. National Institutes of Health. Obes Res 1998;6(Suppl 2):51S-209S. (Erratum in 1998;6:461-2)
9. National Heart, Lung and Blood Institute, North American Association for the Study of Obesity. Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (Publication number 00-4084). National Institute of Health, 2000.
10. Serdula MK, Mokdad AH, Williamson DF, Galuska DA, Mendlein JM, Heath GW. Prevalence of attempting weight loss and strategies for controlling weight. JAMA 1999;282:1353-8.
11. Perri MG. The maintenance of treatment effects in the long-term management of obesity. Clin Psychol Sci Pract 1998;5:526-43.
12. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 1995;3(Suppl 2):211S-6S.
13. Clement K, Vaisse C, Manning BS, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352-4.
14. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998;339:953-9.
15. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-9.
16. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992.
17. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005;129:1430-6.
18. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003;88:4696-701.
19. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20.
20. Mizuno TM, Kelley KA, Pasinetti GM, Roberts JL, Mobbs CV. Transgenic neuronal expression of proopiomelanocortin attenuates hyperphagic response to fasting and reverses metabolic impairments in leptin-deficient obese mice. Diabetes 2003;52:2675-83.
21. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
22. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab 2007;9:282-9.
23. Heshka S, Greenway F, Anderson JW, et al. Self-help weight loss versus a structured commercial program after 26 weeks: A randomized controlled study. Am J Med 2000;109:282-7.
24. Djuric Z, DiLaura NM, Jenkins I, et al. Combining weight-loss counseling with the Weight Watchers plan for obese breast cancer survivors. Obes Res 2002;10:657-65.
25. Rippe JM, Price JM, Hess SA, et al. Improved psychological well-being, quality of life, and health practices in moderately overweight women participating in a 12-week structured weight loss program. Obes Res 1998;6:208-18.
26. Heshka S, Anderson JW, Atkinson RL, et al. Weight loss with self-help compared with a structured commercial program: A randomized trial. JAMA 2003;289:1792-8.
27. Lowe MR, Miller-Kovach K, Phelan S. Weight-loss maintenance in overweight individuals one to five years following successful completion of a commercial weight loss program. Int J Obes Relat Metab Disord 2001;25:325-31.
28. Very low-calorie diets. National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health. JAMA 1993;270:967-74.
29. Rossner S, Flaten H. VLCD versus LCD in long-term treatment of obesity. Int J Obes Relat Metab Disord 1997;21:22-6.
30. Foster GD, Wyatt HR, Hill Jo, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003;348:2082-90.
31. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: A five-year perspective. Int J Obes 1989;13(Suppl 2):39-46.
32. Torgerson JS, Agren L, Sjostrom L. Effects on body weight of strict or liberal adherence to an initial period of VLCD treatment. A randomised, one-year clinical trial of obese subjects. Int J Obes Relat Metab Disord 1999;23:190-7.
33. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: A systematic review of studies published between 1931 and 1999. Obes Rev 2000;1:113-9.
34. Saris WH. Very-low-calorie diets and sustained weight loss. Obes Res 2001;9(Suppl 4):295S-301S.
35. Atkins RC. Dr. Atkins' New Diet Revolution. New York: Harper, 1992.
36. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992;16:269-77.
37. Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003;348:2074-81.
38. Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial. Ann Intern Med 2004;140:778-85.
39. Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: A meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:285-93. (Erratum in 2006;166:932).
40. Howard BV, Manson JE, Stefanick ML, et al, Low-fat dietary pattern and weight change over 7 years: The Women's Health Initiative Dietary Modification Trial. JAMA 2006;295:39-49.
41. Pirozzo S, Summerbell C, Cameron C, Glasziou P. Advice on low-fat diets for obesity. Cochrane Database Syst Rev 2002:CD003640.
42. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: A randomized trial. JAMA 2005;293:43-53.
43. Heilbronn LK, de Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: A randomized controlled trial. JAMA 2006;295:1539-48. (Erratum in 2006;295:2482).
44. Knowler WC, Barrett-Connor E, Fowler SE, et al, for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
45. Fujioka K, Seaton TB, Rowe E, et al, for the Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2:175-87.
46. Garrow JS, Summerbell CD. Meta-analysis: Effect of exercise, with or without dieting, on the body composition of overweight subjects. Eur J Clin Nutr 1995;49:1-10.
47. Klem ML, Wing RR, McGuire MT, Seagle HM, Hill JO. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr 1997;66:239-46.
48. Luque CA, Rey JA. Sibutramine: A serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999;33:968-78.
49. Smith IG, Goulder MA, for the Subutramine Clinical Study 1047 Team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505-12.
50. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84.
51. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study. Am J Clin Nutr 1999;69:1108-16.
52. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from RIO-Europe study. Lancet 2005;365:1389-97. (Erratum in 2005;366:370).
53. Despres JP, Golay A. Sjostrom L, for the Rimbonant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
54. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: Safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005;61:19-27.
55. Korner J, Inabnet W, Conwell IM, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006;14:1553-61.
56. Miller K, Pump A, Hell E. Vertical banded gastroplasty versus adjustable gastric banding: Prospective long-term follow-up study. Surg Obes Relat Dis 2007;3:84-90.
57. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA 1999;281:235-42. (Erratum in 1999;281:1174).
58. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid- 1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 2006;295:761-75. (Erratum in 2006;295:1252).